Transformed Lymphoma

A transformed lymphoma is a lymphoma that was initially diagnosed as indolent (slow-growing) but has transformed into an aggressive (fast-growing) disease.

What causes an indolent disease to suddenly transform into an aggressive one? Added genetic changes to the tumor that occur organically can sometimes put the disease into overdrive, leading to a more aggressive disease.

This doesn't mean that a person whose disease has transformed will only have aggressive cancer cells; rather, that person's tumor will most likely include both indolent and aggressive cancer cells.

For this reason, treatment approaches will focus on the aggressive cells since they present a greater threat to the patient's health than the indolent ones.

Common Transformations

When transformation does occur, it will most commonly be among the following:

  • Follicular lymphoma into diffuse large B-cell lymphoma
  • Marginal zone lymphoma into diffuse large B-cell lymphoma
  • Chronic lymphocytic leukemia into diffuse large B-cell lymphoma (Richter syndrome)
  • Mantle cell lymphoma into blastoid mantle cell lymphoma

Risk of Transformed Lymphoma

What is the risk that a person with follicular lymphoma will have their disease transform into a more aggressive subtype? The risk, according to the Lymphoma Research Foundation, is considerably low: in a patient with indolent lymphoma, the overall risk is between one and three percent per year, with an overall lifetime risk of about 20 percent. Risk goes up each year until ten years, after which time, says the LRF, transformations are rare.

Derived largely from the Lymphoma Research Foundation's Fact Sheet on Transformed Lymphomas (opens as PDF)

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap